Activated natural killer cells - NantKwest

Drug Profile

Activated natural killer cells - NantKwest

Alternative Names: aNK cells - NantKwest; CST-101; Neukoplast; NK-92 cells; ZRx-101

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZelleRx
  • Developer Johann Wolfgang Goethe-Universitat Frankfurt am Main; NantCell; NantKwest; Rush University; University Health Network; University of Pittsburgh Medical Center; ZelleRx
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Natural killer cell receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I/II Pancreatic cancer
  • Phase I Acute myeloid leukaemia; Haematological malignancies
  • Preclinical Hepatocellular carcinoma; Infections
  • No development reported Malignant melanoma; Renal cancer; Solid tumours
  • Discontinued Graft-versus-host disease; Leukaemia; Multiple myeloma; Sarcoma

Most Recent Events

  • 01 Aug 2017 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT03136406)
  • 26 Jul 2017 Final efficacy and adverse events data from a phase I trial in Haematological malignancies released by NantKwest
  • 06 Jun 2017 NantKwest plans to expand the NANT Cancer Vaccine Program and initiate multiple clinical trials in Lung cancer, Breast cancer, Colon cancer, Head and neck cancer, Melanoma, Ovarian cancer, Urothelial cancer, Hodgkins and non-Hodgkins lymphoma, Sarcoma, and Merkel cell carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top